Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory and Autoimmune Disorders

 Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory and Autoimmune Disorders

Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Marketing Authorization in EU

Shots:

  • The EMA’s CHMP has recommended marketing authorization of Amsparity, a biosimilar referencing AbbVie’s Humira
  • Amsparity will be available in a 40 mg pre-filled syringe and pre-filled pen for adults and a 20 mg pre-filled syringe and 40 mg/0.8 mL vial for children. Amsparity showed high bio-similarity data in terms of quality, safety and efficacy to Humira
  • Amsparity is mAb targeting TNFα, act by blocking its interaction with the p55 and p75 cell-surface TNF receptors and is indicated for multiple autoimmune disorders including RA, AS, CD

Click here to­ read full press release/ article | Ref: EMA | Image: STAT

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post